Control of gene expression for gene therapy application requires the design of a sophisticated system embodying multiple properties. The ideal system should present the following features: (1) low or undetectable gene expression in the absence of inducer; (2) strong expression upon induction; and (3) fast kinetics of induction in the presence of inducers and rapid reversal of induction after its withdrawal. To evaluate these parameters, the features of the latest generation tetracycline-sensitive reverse-transactivator (rtTA2 s -M2) alone or in combination with Tet-repressor (tTS-Kid) 
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Tight control of gene expression by a helperdependent adenovirus vector carrying the rtTA2
Introduction
In gene therapy, the use of transcription switches to regulate transgene expression is considered safer and more efficient in many applications. Different control systems have been developed based on orally available small molecules acting at transcription or post-transcriptional levels and capable of activating transcription factors delivered in the context of viral or non-viral vectors (reviewed in Ref. 1) . Among them, the Tet system appears to be the most flexible, as it allows control not only of transcription induction, but also repression of the basal transcription utilizing the same orally bioavailable antibiotic doxycycline (Dox). 2 In the original version, Tet-OFF, the Tet transactivator, tTA 3 in the absence of Dox binds to Tet responsive elements (TREs) and activates transcription. This system, while extensively utilized in transgenic mice, 2 is not ideal for gene therapy applications because termination of gene expression would require continuous pharmacological treatment. In a more interesting version, Tet-ON, the mutated reverse transactivator rtTA, binds DNA and activates transcription in the presence of Dox. 4 Other efforts led to the generation of a 'silencer molecule', in which the N-terminal domain of the chimeric protein tTA was fused to the transcription repressor KRAB domain of the human Kid protein. 5 The use of distinct dimerization domains for the silencer and the transactivator allowed the combination in the same HeLa clones of the two molecules without them reciprocally interfering with each other. Interestingly, this resulted in reduced basal transcription levels and in an increased absolute induction fold. 6 Recently the combination of activator and silencer was utilized in controlling GFP expression in the rat retina upon transgene delivery mediated by a binary adenoassociated vectors (AAV). 7 The rtTA transactivator series was recently improved through the generation of variants called rtTA2 s -S2 and rtTA2 s -M2 which showed better properties (lower leakiness, better inducibility) in HeLa cells and in mice. 8, 9 Another component that affects the efficacy of a controlled transgene expression is the delivery vector itself. The ideal viral vector should not encode for any viral protein, thus avoiding interference in transgene expression. It should be able to accommodate the transgene, as well as the effector molecules in a single vector, and it should be maintained in an episomic form to avoid positional effects due to random integration. The helperdependent adenovirus vectors are the only available vectors that meet these requirements: they are completely devoid of all viral coding sequences, are maintained extrachromosomally and have a large cloning capacity of up to 36 kb. 10 These vectors were successfully utilized in the liver both with the Tet system and with the RU486 based system. 11, 12 However, these previous studies were not designed to establish general rules for achieving maximal level and tightest control of gene expression. Here we address this issue by comparing a set of HD adenovirus vectors carrying the same reporter gene but a variety of tet regulatory elements. The use of the secreted alkaline phosphatase (SEAP) as reporter gene is justified by being an extremely sensitive marker and by allowing repeated non-invasive measurements of gene expression.
Results
HD vectors
To measure the degree of gene regulation a secreted reported gene, SEAP, was utilized. The features of Doxdependent SEAP expression were explored in the context of HD vectors carrying the reporter gene and the rtTA2 s -M2 transactivator in different conditions ( Figure 1 ). As a standard reference of constitutive high level SEAP expression, the reporter gene was cloned under the CMV promoter in the HD-CMV-SEAP vector. In contrast, to obtain Dox-inducible transgene expression, SEAP was inserted under the P min-1 promoter and a vector, HD-Tet-SEAP, containing only this transcriptional cassette, was generated. HD-Tet-SEAP served as control of basal SEAP expression in the absence of any tet-dependent transcription factor. The Dox-inducible rtTA2 s -M2 transactivator was inserted under the control of the strong CMV promoter and the CMV-rtTA2 s -M2 expression unit was inserted in a separate vector named HD-rtTA2 s -M2. To explore the effect of co-delivering the two transcriptional units in a single vector, the SEAP expression cassette was inserted in the proximity of transactivator expression cassette with the two promoters facing each other in a headto-head configuration generating HD-rtTA2 s -M2-SEAP. 
HeLa cells were treated with the positive control HD-CMV-SEAP, with the dual vector system HD-rtTA2s-M2 plus HD-Tet-SEAP or with increasing doses of the single vector HD-rtTA2s-M2-Spacer-SEAP(A). (b) Reduction of basal SEAP expression in HeLa cells in the presence of the silencer molecule. HeLa cells were treated with increasing doses of HD-IRES3-Spacer-SEAP(A), with increasing doses of HD-Tet-SEAP or untreated (mock).
M2-Spacer-SEAP(A) at the dose of 10 2 pp per cell gave rise to a high level of SEAP expression similar to that observed in the same cells treated with HD-CMV-SEAP, where SEAP is under the CMV promoter. Similar levels of SEAP regulation as a function of Dox treatment were obtained with HD-rtTA2 s -M2-Spacer-SEAP(S), which contains the reporter expression cassette in the opposite orientation (data not shown). These results suggest that in the context of HD vectors orientation of transcriptional cassette does not affect transgene expression in agreement with previous observations. 13 Nevertheless, increasing the number of pp per cell in HD-rtTA2 3 and 10 4 pp/cell in the absence of Dox, showed SEAP expression at basal levels as in untreated cells (mock). Similar results were obtained with the HD-IRES-SEAP (data not shown). Differently, treatment with HD-Tet-SEAP, which contains only the reporter expression cassette, showed SEAP levels higher than mock cells at the dose of 10 4 pp/cell. In the presence of Dox, a remarkable level of SEAP expression was observed with an almost 100 000-fold induction at the highest vector dose.
These results indicate that in the context of HD vectors the use of the silencer molecule is effective in reducing basal reporter gene expression to the same level as mocktreated cells.
Dox-dependent SEAP expression in C57/B6 mice
Regulated gene expression has been explored in vivo through targeting many tissues including retina, tumors, liver and muscle.
1 Genes encoding for a secreted reporter or therapeutic proteins are often injected in the muscle as an easy accessible tissue and safer organ. We, therefore, chose this tissue to explore the degree of SEAP inducibility achievable by the HD vectors carrying the Tet regulation system. To this end, C57/B6 mice were injected i.m. with HD vectors and SEAP released in the serum measured at day 2, 4 and 7 p.i. Starting from day 2, a subgroup of mice was treated with Dox in the drinking water at the dose of 200 g/ml (Figure 3a s -M2-Spacer-SEAP(S) and not treated with Dox resulted in 5-10 ng/ml SEAP in the serum at day 7 p.i., which is above the level observed in mock-injected mice (below 1 ng/ml).
To reduce SEAP expression in uninduced conditions, C57/B6 mice were injected with HD-IRES3-Spacer-SEAP or HD-IRES3-SEAP at a dose of 10 9 pp and treated as described above (Figure 3b) . Indeed, in the absence of induction, SEAP was not released in the serum at any time-point analyzed as in the negative control HD-Tet-SEAP. In the presence of Dox, the kinetics of SEAP expression was similar to HD-rtTA2 s -M2-Spacer-SEAP(A) with a maximal activity at day 7 p.i. At this time-point, serum SEAP levels reached those observed in mice treated with the control vector HD-CMV-SEAP.
These data showed that the use of the transcription activator alone yielded a serum SEAP level above that observed with HD-CMV-SEAP, but that the basal SEAP expression in the uninduced condition can be reduced to mock levels only when the silencer is present. 
Repetitive induction of SEAP expression in
pp: HD-CMV-SEAP (filled squares); HD-IRES3-Spacer-SEAP (asterisks); HD-IRES3-SEAP (open triangles); HD-Tet-SEAP (crossed).
injected because of the high degree of immunogenicity of the SEAP protein. Intramuscular injection of HD-rtTA2 s -M2-Spacer-SEAP(A) at the dose of 10 9 pp showed high SEAP levels in induced condition, which returned to basal level in 10-15 days upon Dox withdrawl ( Figure  4a ). Expression was reinduced at similar levels several times as a function of Dox treatment.
We next wished to ascertain if the silencer molecule could affect the kinetics of reversal of induction ( Figure  4b ). To this end, nude mice were injected i.m. with 10 9
Figure 4 Repetitive SEAP induction in Balb/C nude mice. Mice were injected i.m. (quadriceps) at a dose of 10 9 pp and treated at different timepoints with Dox (200 g/ml in the drinking water) as indicated by the horizontal bars. A group of uninjected mice (filled triangles) was used to measure the basal level of SEAP activity in both panels. Values of serum SEAP are mean ± s.d. (n = 5). (a) Repetitive induction of SEAP expression in mice injected with HD-rtTA2 s -M2-Spacer-SEAP(A) (filled rhomboid). The vector was also injected in a group of immunocompetent Balb/C mice (dashed line). (b) Basal SEAP expression is reduced to background level in mice injected with rtTAS2 s -M2/silencer expressing vector. Vectors: HD IRES-Spacer-SEAP (asterisks); HD CMV SEAP (squares); HD-Tet-SEAP (rhomboids).
pp of HD-IRES-Spacer-SEAP in parallel with the HD-Tet-SEAP vector as control of basal SEAP expression and with the HD-CMV-SEAP vector as control of maximal expression. Intramuscular injection of HD-CMV-SEAP yielded stable SEAP expression over time, in the range of 1000 ng/ml, whereas in immunocompetent Balb/C mice similar SEAP expression levels were observed only at early time-points. Mice injected with HD-IRES-Spacer-SEAP and treated with Dox showed a serum SEAP level of 500 ng/ml, which returned to background level in 10-15 days upon Dox withdrawl. Repetitive induction confirmed that the kinetics of expression were strictly depen-dent on Dox treatment. At this vector dosage, C57/B6 mice injected with the HD-Tet-SEAP vector did not show detectable SEAP levels. Therefore, HD-IRES3-Spacer-SEAP allows SEAP expression to be regulated from levels observed in uninjected mice (mock) to the positive control HD-CMV-SEAP.
Kinetics of SEAP expression as a function of a fixed amount of Dox
In the previous experiments, we have used a convenient Dox treatment where Dox was delivered in the drinking water at a concentration of 200 g/ml. With this regimen, the amount of Dox per mouse is much higher than that currently used in antibiotic therapy and cannot be precisely correlated with SEAP expression levels. Dox is used in human therapy at a dose of 100 mg per day equivalent to approximately 1.4 mg/kg of body weight. Taking into account the 10-fold faster pharmacokinetics of this drug in the mouse, a serum level equivalent to that obtained in antibiotic therapy is reached with a dosage of 14 mg/kg delivered by gavage.
14 Under this Dox treatment, SEAP levels rose to a plateau (1000 ng/ml) in 2 days, were maintained stable for 2 days and decreased to basal levels in 5 days upon Dox withdrawl (Figure 5a ). To further characterize the kinetics of reversal of induction, the half-life of the SEAP protein was measured in a group of mice (Figure 5b) . Injection of 1000 ng of recombinant SEAP protein decreased to basal levels in 5 days with a terminal half-life of 22 h.
These experiments indicate that the degree of Doxmediated regulation is maintained at a fixed amount of Dox and that the reversal of induction is largely dependent on the long SEAP half-life.
Discussion
In this paper, we analyze Dox-dependent transgene expression in the muscle using as delivery vehicle HD vectors. These large cloning capacity vectors allow simultaneous delivery within a single transducing particle of both the transgene and one or more transcriptional regulators. Furthermore, the reporter transgene SEAP, because of its high dynamic range, allows minimal levels of gene expression to be detected and to establish very precisely the degree of transcriptional leakiness and gene expression inducibility.
The advantage of using a single vector such as HDrtTA2 s -M2-Spacer-SEAP carrying all the genetic components, was evident in a direct comparison with a binary system composed of a HD-rtTA2 s -M2 and HD-Tet-SEAP vectors. Although successful regulation of SEAP expression was observed in HeLa cells (Figure 2a) , in the muscle a high degree of regulation was observed only with the HD-rtTA2 s -M2-Spacer-SEAP(A) or HD-rtTA2 s -M2-Spacer-SEAP(S) vectors at the dose of 10 8 pp ( Figure  3a) . In addition, these results indicate that in the context of HD vector using the spaced configuration reporter gene expression is not affected by the orientation of transcriptional unit, as also reported by a recent publication. 13 In contrast, orientation constraints were observed previously in first generation adenovirus vectors 15 or plasmid vectors carrying the tet inducible system in a single plasmid. 9 These results suggest that a single vector system, where the transcriptional units are separated by a non-coding region, offer a wider operational opportunity Gene Therapy in particular towards low doses, which may be considered safer and more applicable in a larger animal model.
The majority of the HD vectors described here utilize the CMV promoter, which was shown to be the strongest promoter available in the context of first generation Ad vectors. 16 However, in mice injected with HD-rtTA2 s -M2-Spacer-SEAP, the SEAP expression shown was higher than in mice injected with HD-CMV-SEAP which express SEAP directly under the control of CMV promoter. Many technical differences can explain this result, such as the physical particles/transducing particles ratio present in the two vector preparations. Nevertheless, it is worth mentioning that a similar expression pattern was observed in HeLa cells (Figure 1 ) indicating that this ratio was comparable. Although it may be premature, this result leads to the speculation that rtTA2 s -M2 binding to multiple Tet binding sites in the P tet-1 min promoter is favored in multinucleated muscle cells leading to a higher SEAP expression. Further experiments are required to explain this difference in SEAP expression.
The drawback of the HD-rtTA2 s -M2-Spacer-SEAP(A) or HD-rtTA2 s -M2-Spacer-SEAP(S) vectors is leaky transgene expression in the uninduced condition, which was not revealed in the control vector HD-Tet-SEAP even at a 10-fold higher dose (Figure 3b) , indicating a residual affinity of rtTA2 s -M2 for its binding site in the absence of Dox. This limitation was overcome by introducing the silencer molecule in the HD-IRES3-Spacer-SEAP vector. In HeLa cells, HD-IRES3-Spacer-SEAP allowed a degree of regulation similar to that previously observed with stable HeLa clones carrying the rtTA and silencer components. 6 In addition, the almost 100 000-fold induction is one of the highest level of induction ever reported with gene therapy vectors in the presence of an undetectable basal expression in uninduced conditions.
The introduction of the silencer molecule in HD-IRES3-Spacer-SEAP not only abolishes the reporter expression in uninduced conditions, but also achieves SEAP expression level in induced conditions, similar to the control vector HD-CMV-SEAP (Figure 4b ). This evidence extends the use of the silencer molecule to HD vectors, and more generally to adenovirus-derived vectors, without affecting the potency of transgene expression. In addition, the presence of a silencer also allowed tight control of SEAP expression in a head-to-head configuration as shown with HD-IRES-SEAP (Figure 3b) . The small size of this configuration is within the packaging limits of other gene therapy vectors such as lentivirus, where the tet-transactivation/silencer system may offer new opportunities for intervention. However, the tettransactivator/silencer system was explored previously in a dual AAV system where the rtTA and the silencer were delivered with one vector and the reporter gene with a second one. 7 Injection of these vectors in the eye resulted in almost 100-fold lower expression of an inducible GFP compared with the GFP cloned directly under the CMV promoter. The use in our experiments of the last generation rtTA2 s -M2 transactivator, as well as the co-delivery of all elements in a single vector may explain, at least in part, the different results. Indirect comparison with other regulation systems previously tested in the muscle showed that our approach offers a higher degree of regulation in the absence of leaky expression. Indeed, the RU486 system delivered i.m. as plasmid DNA showed poor level of regulation with a marginal increase over the high basal levels of expression. 17 Similarly, the Rapamycin system explored in mice injected i.m. with Ad or AAV vectors, resulted in a lower level of inducibility in both delivery systems. 18 Another interesting aspect emerging from the in vivo studies is the rapid return to base line after drug withdrawal. Differently to what we observed previously using the mIFN␣ as transgene, 12 the reversal of SEAP induction was slower. However, SEAP showed a longer half-life that requires 5 days to reach the basal level. This observation can explain, at least in part, the slower reversal of induction showed in Figure 5 . More importantly, we have shown that a Dox regimen in mice corresponding to a clinically accepted dose of the drug in humans, causes a significant regulation of transgene expression.
In conclusion, we propose that in those gene therapy applications where strong expression is required, it is advantageous to utilize the HD-rtTA2 s -M2 approach, whereas in applications where the basal level has to be tightly controlled the HD-IRES system may offer new possibilities for intervention.
Materials and methods
HD vectors
To explore different expression cassettes and different vector architecture, a new HD construction protocol was utilized which is based on a packaging system. 19 Briefly, the pC4HSU backbone 20 was inserted in a cosmid plasmid and recombinants rescued by in vitro packaging system on the basis of the advantageous packaging of larger genome and counter selection against a toxic gene.
As a reference for SEAP expression levels, the transgene was inserted in the pViJ plasmid 21 under the control of the CMV promoter/enhancer generating pViJ-SEAP. This expression cassette was moved into the pC4HSU backbone (pHD-CMV-SEAP). To achieve a Dox controlled SEAP expression, a P tet-1 -SEAP expression cassette was generated where the transgene was inserted under the control of the tet responsive promoter, P tet-1 , downstream of the synthetic intron from pCAT3basic (Clontech, Palo Alto, CA, USA) and followed by the bGH polyadenylation signal. This expression cassette was inserted in pC4HSU generating pHD-Tet-SEAP. To express the rtTA2 s -M2 transactivator the CMV promoter was utilized followed by intron A and the SV40 polyadenylation signal. This expression unit was inserted in the C4HSU backbone resulting in pHD-rtTA2 s -M2 or preassembled with P tet-1 -SEAP in a head to head configuration, and then moved into pC4HSU backbone vector generating the pHD-rtTA2 s -M2-SEAP. To separate the reporter expression cassette and the effector molecule, P tet-1 -SEAP was inserted in both orientation in pHDrtTA2 s -M2 at 5 kb from the transactivator expression cassette, producing two vectors pHD-rtTA2 s -Spacer-M2-SEAP(A) and pHD-rtTA2 s -Spacer-M2-SEAP(S). To express the silencer molecule, 6 the CMV-rtTA2 s -M2 expression cassette was modified by inserting the internal ribosome entry site (IRES) from pIRES (Clontech) of the encephalomyocarditis virus (ECMV) which allows translation of two open reading frames from one messenger RNA. The silencer molecule was inserted downstream of the rtTA2 s -M2 gene followed by the polyadenylation site. The CMV-rtTA2 s -M2-Silencer expression cassette was cloned in the head to head configuration with the P tet-1 -SEAP cassette generating pHD-IRES3-SEAP vector and in the spaced configuration in pHD-Tet-SEAP leading to pHD-IRES3-Spacer-SEAP vector.
To rescue HD vectors, plasmids were cleaved with PmeI, transfected into 293cre4.15 cells and infected with the helper AdH14. 12 Multiple viral passages were performed to reach a high titer which was monitored by TaqMan PCR measurements as previously described. 20 All the vectors were purified on a CsCl density gradient, and physical particles (pp) were measured by DNA optical density.
Tissue culture and animals
HeLa cells were culture in D-MEM supplemented with 10% FBS. Six-week-old female Balb/C, Balb/C nude, and C57Bl/6 were purchased from Charles River (Lecco, Italy). Vectors were diluted in PBS and injected into the quadriceps in 50 l final volume. Doxycycline HCl (Sigma, St Louis, MO, USA) was dissolved in drinking water at a final concentration of 200 g/ml in 5% sucrose, pH 6.0. For dose-response experiments, a dose of 280 g/100 l (15 mg/kg) was dissolved in 100 l of 8% EtOH 46% PEG200 and 46% H 2 O and administered orally by gavage.
SEAP assay and pharmacokinetics
To reduce background phosphatase activity, mice serum and HeLa supernatants were treated at 65°C for 30 min. To measure SEAP activity, a chemiluminescent reporter assay system was used according to manufacturer's instructions (Applied Biosystems, Foster City, CA, USA). Lights units were measured for 1 s/well in luminometer (TopCount2).
To measure terminal SEAP half-life, recombinant SEAP was produced in transient transfected HeLa cells and concentrated with Centricon YM10 (Millipore, Bedford, MA, USA). SEAP was injected as an i.v. bolus (30 s) in the tail vein of female C57/B6 mice. At established intervals blood was collected and serum SEAP levels measured as indicated above. Pharmacokinetic analysis was performed using a WinNolin's noncompartimental analysis (WinNonlin.3 program; Pharsight). Terminal half-life was estimated using linear/log trapezoidal rule and noncompartmental parameters were extrapolated to infinity.
